Authors
Latest:
Americans Say Drug Costs Are Too High, and They Are RightThe executive director of the Biosimilars Forum calls for policies to support adoption of lower-cost biologics.
Latest:
Cimerli Offers a New, Interchangeable Biosimilar for Ocular ConditionsCimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective vascular endothelial growth factor inhibition.
Latest:
Dr Lakesha Farmer Highlights Current Biosimilar Education, Acceptance EffortsCencora's Lakesha Farmer, PharmD, MBA, discusses efforts that health care organizations can take to better educate patients and providers on biosimilars to improve biosimilar acceptance and achieve cost savings associated with these products.
Latest:
Opinion: Purple Book Patent Listings Are Only a First StepIntellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.
Latest:
Budget Impact Analysis of Biosimilar Natalizumab in the USProjected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Latest:
Escaping the Void: All Things Biosimilars With Craig & GTo close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Latest:
Budget Impact Analysis of Biosimilar Natalizumab in the USProjected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Latest:
Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.
Latest:
The Pandemic's Multilevel Effect on Patient AccessCoronavirus disease 2019 altered the workflow in all areas of the health care and life sciences industries, and the FDA was not exempt from pandemic-induced upheaval.
Latest:
AmerisourceBergen Rep Previews the Year Ahead for Biosimilars: What’s Coming Down the Pipeline in 2022?Sean McGowan, senior director of Biosimilars for AmerisourceBergen, forecasts potential biosimilar approvals and launches in 2022 as well as offers insights into how emerging biosimilars will impact the market and pricing in the coming years during an interview.
Latest:
Understanding the Risks, Opportunities, and Prospects of Biosimilars in 2020 and BeyondHurdles to a vibrant biosimilar market are not as insurmountable as they appear.
Latest:
Positioning Biosimilar Ustekinumab Early Reduces Burden on Spain's National Health SystemEarly use of ustekinumab biosimilars in Spain shows cost-effective Crohn disease care, boosting QALYs and cutting NHS spend—insights for Europe.
Latest:
New Rule: Transition to BLA Pathway Is CompleteAs of today, the FDA has completed a 10-year process to bring a wider set of biologics under the biologics license pathway for approval.
Latest:
Follow the Science: Bridging the Biosimilar Gap With Dr Hillel CohenExplore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization in this engaging podcast episode.
Latest:
Drug Couponing: Better or Worse for Biosimilars?Payers will have to carefully mull limited options.
